Navigation Links
Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations

ASHBURN, Va., Sept. 26 /PRNewswire/ -- Innocoll, Inc., a privately-held specialty pharmaceutical company, announced the following status and progress updates regarding its clinical development programs and specialty pharmaceutical operations:

- Three Investigational New Drug (IND) Applications already approved

in 2007.

- GENTAMICIN SURGICAL IMPLANT to commence two US phase 3 multi-centered

clinical trials for the prevention of surgical site infection.

- CollaRx(R) GENTAMICIN TOPICAL to commence a series of phase 2 clinical

trials for the treatment and prevention of infected diabetic foot


- BUPIVACAINE SURGICAL IMPLANT to commence a series of phase 2 clinical

trials for the management of post-operative pain in a variety of soft

tissue and orthopedic surgery models.

- First patient dosing in at least five different clinical trials (three

in phase 2 and two in phase 3) expected before the end of 2007.

- IND submission planned for CollaRx(R) BUPIVACAINE TOPICAL, a new product

opportunity for the management of painful chronic and acute wounds.

- US Launch of CollaGUARD(TM), an advanced wound care product developed by

Innocoll and its first to be launched in the US, is planned for the

fourth quarter 2007.

- European sales and marketing infrastructure sold to EUSA Pharma in

August 2007.

Commenting on the update, Dr. Michael Myers, President and CEO of Innocoll Inc., said, "Our successes over the past few months have established a solid platform on which to build the future growth of the business. We are looking forward to the launch of our first product in the US with CollaGUARD and are poised to commence the clinical development of an exciting portfolio of late- stage pharmaceutical products. According to recent market research performed by L.E.K. Consulting, these three products between them have projected ann

SOURCE Innocoll, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
3. XTL Provides Update on Phase I Clinical Trial of XTL-2125
4. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
5. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
6. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
7. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
8. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
9. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
10. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
11. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
(Date:9/23/2014)... September 23, 2014 Avillion ... the appointment of Jarrod Longcor as ... is responsible for structuring, negotiating and executing successful ... well as providing management and strategic leadership to ... Executive leadership team. Mr Longcor brings ...
(Date:9/22/2014)... , September 23, 2014 , ... health authorities, increasing rigor for trial master file (TMF) ... industry,s largest TMF survey to date reveals an increase ... to provide auditors with remote access to their electronic ... owners surveyed in the Veeva 2014 Paperless ...
(Date:9/22/2014)... Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ... $200 million of its common stock in an underwritten ... Merrill Lynch are acting as joint book-running managers for ... option to purchase additional shares of its common stock. ... offering are being sold by Avanir.  The offering is ...
Breaking Medicine Technology:Avillion Appoints Jarrod Longcor as Chief Business Officer 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 3Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 4Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 3
... March 15 URL Pharma, Inc. today announced the launch of an expanded ... eligible for low-cost Colcrys therapy. Uninsured and Medicare Part D patients with household incomes ... Colcrys PAP. This expanded program is available to patients immediately. , ... ...
... , March 15 Watson Pharmaceuticals, Inc. ... subsidiary, Watson Laboratories, Inc. – Florida , has ... (FDA) for its Abbreviated New Drug Application (ANDA) for ... Laboratories International SRL,s Cardizem® LA product.  Watson intends to ...
Cached Medicine Technology:URL Pharma Expands Colcrys(R) Patient Assistance Program 2URL Pharma Expands Colcrys(R) Patient Assistance Program 3URL Pharma Expands Colcrys(R) Patient Assistance Program 4URL Pharma Expands Colcrys(R) Patient Assistance Program 5URL Pharma Expands Colcrys(R) Patient Assistance Program 6Watson Receives FDA Approval for Generic Cardizem(R) LA 2Watson Receives FDA Approval for Generic Cardizem(R) LA 3
(Date:9/23/2014)... Royal Sport Ultra Clean 100 is the ... of premium sports nutrition products. Its gluten free formula ... without artificial colors or dyes, fillers, added sugar and ... shelves at select GNC retailers, on, and through ... a limited time special on its products. Customers can ...
(Date:9/23/2014)... ADOMANI, Inc. has announced that ... CEO. He is a 13-year veteran in the school, commercial ... of A-Z Bus Sales of Colton, California. While with A-Z ... their top line revenues, profit and market penetration by double ... diesel to all-electric or plug-in hybrid vehicle conversions. They ...
(Date:9/23/2014)... 23, 2014 Airbus Helicopters Inc. (AHI) ... honored as the 2014 Vision Zero Aviation Safety ... database, a free flight safety service the company ... Manager - Air Medical Specialist for Airbus Helicopters Inc., ... $10,000 check during the Air Medical Transport Conference Annual ...
(Date:9/23/2014)... issue of the European Journal of Cancer ... presented during the 1st EORTC Cancer Survivorship Summit held ... targeted therapeutics, and more personalized multimodal treatments has boosted ... a large and rapidly increasing number of cancer survivors. ... with a broad spectrum of late adverse treatment effects ...
(Date:9/23/2014)... a driving force behind many chronic diseases, especially ... inflammation caused by conditions such as viral hepatitis ... options. Now, scientists at Virginia Commonwealth University Massey ... in preclinical studies that blocking the expression of ... halts the development and progression of liver cancer ...
Breaking Medicine News(10 mins):Health News:Sports Nutrition Brand, Royal Sport LTD, Introduces 'Clean,' Gluten Free Protein Supplement, Royal Sport Ultra Clean 100™ 2Health News:ADOMANI Announces Jim Reynolds to Take Over as President and CEO 2Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 2Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 3Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 4Health News:Study uncovers genetic driver of inflammation, uses it to prevent and treat liver cancer 2
... the major arterial blood vessels. It is one of the ... IL-1 has been linked to atherosclerosis and a clinical trial ... is being studied for its effects on the severe clinical ... a team of researchers led by Gary Owens, at the ...
... By Steven Reinberg HealthDay Reporter , MONDAY, ... may see their IQ improve, Norwegian researchers have found. ... earlier studies did not rule out the possibility that people ... education than others, the researchers noted. Now, however, ...
... like regular schedules for meal, bath, and bed times ... with oral and tactile sensitivities, such as discomfort at ... rituals could be an early warning sign of adult ... Reuven Dar of Tel Aviv University,s Department of Psychology, ...
... Teens are more likely to be obese if they had ... toddlers, according to a new study. The findings echo ... ties with their parents were more likely to be obese ... the latest study, researchers examined U.S. National Institute of Child ...
... News) -- Being hospitalized during the holidays can be emotionally ... spirits up, experts say. "While the psychological impact ... be well and home than sick and away," Joshua Klapow, ... (UAB), explained in a university news release. "The ...
... A global team of neuroscientists, led by researchers at ... for a brain disorder that may be much more common ... Nature Genetics , the researchers say they ... to development of hereditary diffuse leukoencephalopathy with spheroids ...
Cached Medicine News:Health News:More Schooling Might Raise IQ 2Health News:More Schooling Might Raise IQ 3Health News:Childhood hypersensitivity linked to OCD 2Health News:Mother-Toddler Bond May Influence Teen Obesity 2Health News:A Visit Can Bring Holiday Cheer to Hospitalized Patients 2Health News:'Rare' brain disorder may be more common than thought, say Mayo Clinic scientists 2Health News:'Rare' brain disorder may be more common than thought, say Mayo Clinic scientists 3
DS 7600 Central Station...
... MedSystem III DLE (Drug List Editor) Multi-Channel ... drug infusion technology. The instrument combines three ... clinical versatility in an unparalleled small size. ... MedSystem III Infusion System simplifies the delivery ...
... Freedom Chart Manager provides powerful workflow tools ... management, integrated transcription services, and customized flow ... that eliminates the need for paper charts. ... of a paperless office now and can ...
... ChartingPlus proves itself to over 2,000 ... Designed with the user in mind, ChartingPlus ... powerful and dynamic features to improve documentation ... practice. Our medical content is ...
Medicine Products: